A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia

Study acronym: LAZURE
StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Primary and study completion dates changed from estimate of Sep 30, 2026 to Sep 3, 2026
    • Secondary endpoints: details revised at 3 of 6 entries
    • Eligibility criteria shortened, about 2 words
  2. Re-verified, no change to tracked fieldsv6
  3. Trial status changed: Recruiting → Active, Not Recruiting
    • Study sites: 9 to 8
    v5
  4. Re-verified, no change to tracked fieldsv4
  5. Site details revised at 3 of 9 sitesv3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 8 to 9
    • Start date changed from estimate of Oct 24, 2025 to Nov 13, 2025
    v2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
729 trials monitored
See 62 trials at risk
This is a study to investigate the effect of AZD0780 tablets on low density lipoprotein cholesterol levels (LDL-C) compared with placebo tablets administered in combination with rosuvastatin tablets in adult Russian participants with dyslipidaemia. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study. The total length of the study for an individual participant will be up to 136 days, including a screening period of up to 14 days, rosuvastatin run-in period of 28 days, treatment with AZD0780 or placebo for 84 days, and a safety follow-up period of 10 days.
Trial Details
NCT Number NCT07218900
Lead Sponsor AstraZeneca
Conditions
(from sponsor)		 Dyslipidaemia
Related terms Dyslipidemias
Enrollment 76 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov